NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	52.38M 0 45.67M 42.3M 39.6M 74.27M 4.94B 74.71M 502M 194M 2.43B 197M 192M 8.45B	P/E 2024 *	-	P/E 2025	-2.81x
Enterprise Value	50.54M 0 44.06M 40.81M 38.2M 71.65M 4.77B 72.08M 484M 188M 2.35B 190M 186M 8.15B	EV / Sales 2024 *	-	EV / Sales 2025	-
Free-Float	35.62%	Yield 2024 *	-	Yield 2025	-

15/06	NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology Platform	CI
27/05	Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes	RE
27/05	NewcelX Submits Pre-IND Package To FDA For NCEL-101 For The Treatment Of Type 1 Diabetes	CI
01/05	NewcelX Ltd. announced that it has received $1.349994 million in funding	CI
30/04	NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
29/04	NewcelX Ltd. Auditor Raises 'Going Concern' Doubt	CI
20/04	Newcelx updates corporate presentation to highlight type 1 diabetes flagship program	RE
02/04	NewcelX Ltd. announced that it expects to receive $1.349994 million in funding	CI
09/03	NewcelX announces strategic collaboration with Eledon Pharmaceuticals to advance NCEL-101 program for type 1 diabetes	RE
12/01	Newcelx Ltd. Announces Positive Results from International Collaborative Study	CI
06/01	NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory Board	CI
17/11	NewcelX Ltd. Announces Appointment of Prof. Jeremy Shefner to the Scientific Advisory Board	CI
07/11	NewcelX Ltd. Announces Chief Financial Officer Changes, Effective December 10, 2025	CI

27/05	NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes	GL
30/04	NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026	AQ
20/04	NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference	GL
01/04	NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing	GL
09/03	NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes	PR

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KADIMASTEM	-.--%	-8.93%	-	-	17.82M
LONZA GROUP AG	+1.44%	+1.71%	-10.63%	-9.16%	42.75B
REVOLUTION MEDICINES, INC.	+0.37%	+9.22%	+308.19%	+562.02%	34.65B
BEONE MEDICINES AG	+2.84%	+3.80%	+6.87%	+34.93%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.34%	+8.51%	-22.34%	28B
CELLTRION, INC.	-1.90%	+2.47%	+10.18%	+18.13%	24.83B
ASCENDIS PHARMA A/S	+1.22%	+7.06%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-3.13%	+52.04%	+107.47%	13.14B
EUROFINS SCIENTIFIC SE	-0.57%	-2.43%	+5.18%	+4.20%	12.61B
IONIS PHARMACEUTICALS, INC.	-0.26%	+0.41%	+100.27%	+80.69%	12.25B
Average	+0.35%	+0.55%	+60.08%	+96.99%	23.62B
Weighted average by Cap.	+0.74%	+0.91%	+65.06%	+113.03%

	2024	2025
Net sales	-	-
Net income	-26.55M -0 -23.15M -21.44M -20.07M -37.64M -2.51B -37.87M -254M -98.58M -1.23B -99.67M -97.53M -4.28B	-8.3M -0 -7.24M -6.7M -6.27M -11.77M -783M -11.84M -79.51M -30.82M -385M -31.16M -30.49M -1.34B
Net Debt	7.35M 0 6.41M 5.93M 5.55M 10.42M 693M 10.48M 70.38M 27.28M 341M 27.58M 26.99M 1.18B	-1.85M -0 -1.61M -1.49M -1.4M -2.62M -174M -2.63M -17.68M -6.85M -85.74M -6.93M -6.78M -298M

Kadimastem Stock TEL AVIV STOCK EXCHANGE

Stocks

KDST

IL0011284614

Biotechnology & Medical Research

Valuation: Kadimastem

Chart: Kadimastem

Latest news : Kadimastem

Analysts' recommendations: Kadimastem

Press Releases: Kadimastem

Other Biotechnology & Medical Research

Financials

Company Profile